To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.
Summary
HR9421, introduced June 24, 2026, would require in-person visits and state-licensed prescribers for mifepristone, restricting telehealth access. For $LLY, this sets a precedent that could limit telehealth prescribing of REMS-restricted drugs like tirzepatide, potentially slowing revenue growth from the obesity drug market.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9421 restricts mifepristone to in-person prescribing, directly affecting telehealth abortion providers but not listed pharma companies.
- 2.For Eli Lilly ($LLY), the bill sets a regulatory precedent that could extend in-person requirements to other REMS drugs like tirzepatide, increasing compliance costs and limiting market reach.
- 3.The bill is in very early procedural stages—only referred to committee—with minimal momentum; near-term market impact is negligible.
Market Implications
The healthcare sector faces low direct impact from HR9421, but $LLY and potentially $JNJ (with its own REMS drugs) are most exposed to future precedent. Investors should watch for committee amendments that broaden the bill's scope to include other REMS drug classes. Near-term, no significant stock price moves are expected from this single bill given its procedural status.
Full Analysis
On June 24, 2026, Representative Sheri Biggs (R-SC3) introduced HR9421, a bill to prohibit REMS-certified providers from prescribing mifepristone without an in-person visit and a state medical license. The bill was referred to the House Energy and Commerce Committee. It is an early-stage procedural action with 2 cosponsors and no companion bill, indicating limited legislative momentum.
The bill imposes no direct funding or spending changes; its mechanism is a regulatory restriction on prescribe and dispense protocols for mifepristone, a drug used for medication abortion. The REMS program (Risk Evaluation and Mitigation Strategy) already requires certification; this bill adds in-person visit and state-license requirements, effectively ending telehealth-based prescribing of the drug.
No direct convergence with other bills or presidential actions is identified in the provided data. The analysis is isolated to this bill's specific provisions.
For Eli Lilly ($LLY), this bill is a negative regulatory signal. While Lilly does not manufacture or market mifepristone, its blockbuster obesity drug tirzepatide (Zepbound) is subject to a REMS program due to safety concerns (e.g., thyroid C-cell tumors). Tirzepatide has seen rapid adoption via telehealth platforms, which have expanded access to obesity care. HR9421 creates a legislative template that could be applied to other REMS drugs, including tirzepatide. If similar restrictions were imposed, Lilly's revenue growth from the obesity market could slow as patient access contracts. With Lilly's FY2025 revenue at $34.1B and tirzepatide sales estimated at $15-20B annually, any restriction on telehealth prescribing would materially impact revenue. However, the bill only directly affects mifepristone, making the link to Lilly indirect and inferential; confidence is lowered accordingly.
No market data on stock price movements is provided. The impact of this single early-stage bill on publicly traded companies is minimal. The legislative path requires committee markup, House floor vote, Senate introduction/passage, and presidential signature—all unlikely given the bill's partisan nature and limited co-sponsorship.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
New in-person visit and state-license requirement for REMS-certified providers to prescribe mifepristone.
Who must act
REMS-certified healthcare providers prescribing mifepristone for medication abortion, and the telehealth and pharmacy distribution systems supporting them.
What happens
Restricts telehealth prescribing of mifepristone, reducing patient access and market volume for mifepristone and potentially for other REMS-restricted drugs in the future.
Stock impact
Eli Lilly does not market mifepristone; however, its obesity drug tirzepatide (Mounjaro/Zepbound) is under similar REMS scrutiny for telehealth prescribing. This bill sets a regulatory precedent that could tighten in-person requirements for other REMS drugs, increasing Lilly's patient acquisition costs and limiting the rapid revenue growth from telehealth-enabled prescribing of tirzepatide.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
HELP Copays Act
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
To amend the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to require health insurance coverage of drugs indicated for the treatment of autoimmune diseases and certain blood disorders.
Wildlife Health Coordination and Zoonotic Disease Prevention Act of 2026
INSULIN Act of 2026
Maternal Health Pandemic Response Act
To amend subsection (q) of section 505 of the Federal Food, Drug, and Cosmetic Act to clarify the process for denying certain petitions whose primary purpose is to delay the approval of an application submitted under subsection (b)(2) or (j) of such section 505, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →